Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis

Bibliography

• GRaghu, HRCollard, JJEgan, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824
   PubMed Web of Science ®Google Scholar
• BLey, HRCollard. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013;5:483-92
   PubMedGoogle Scholar
• VSTaskar, DBCoultas. Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc 2006;3(4):293-8
   PubMedGoogle Scholar
• JSLee, HRCollard, GRaghu, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med 2010;123(4):304-11
   PubMed Web of Science ®Google Scholar
• MYArmanios, JJChen, JDCogan, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356(13):1317-26
   PubMed Web of Science ®Google Scholar
• INoth, YZhang, SFMa, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013;1(4):309-17
   PubMed Web of Science ®Google Scholar
• TJGross, GWHunninghake. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345(7):517-25
   PubMed Web of Science ®Google Scholar
• RMStrieter, BMehrad. New mechanisms of pulmonary fibrosis. Chest 2009;136(5):1364-70
   PubMed Web of Science ®Google Scholar
• SBMargolin, SLefkowltz. Pirfenidone: a novel pharmacologic agent for prevention and resolution (removal) of lung fibrosis. FASEB J 1994;8(4):A382
   Google Scholar
• HOku, TShimizu, TKawabata, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590(1-3):400-8
   PubMed Web of Science ®Google Scholar
• HLiu, PDrew, ACGaugler, et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 2005;5(6):1256-63
   PubMed Web of Science ®Google Scholar
• HNakazato, HOku, SYamane, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002;446(1-3):177-85
   PubMed Web of Science ®Google Scholar
• KMAntoniou, MGAlexandrakis, KSfiridaki, et al. Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis 2004;21(2):105-10
   Google Scholar
• GRaghu, KKBrown, WZBradford, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350(2):125-33
   PubMed Web of Science ®Google Scholar
• TEKingJr, CAlbera, WZBradford, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374(9685):222-8
   PubMed Web of Science ®Google Scholar
• PWNoble, CAlbera, WZBradford, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760-9
   PubMed Web of Science ®Google Scholar
• TEKingJr, WZBradford, SCastro-Bernardini, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083-92
   PubMed Web of Science ®Google Scholar
• AAzuma, TNukiwa, ETsuboi, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171(9):1040-7
   PubMed Web of Science ®Google Scholar
• HTaniguchi, MEbina, YKondoh, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010;35(4):821-9
   PubMed Web of Science ®Google Scholar
• AAzuma, YTaguchi, TOgura, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. Respir Res 2011;12:143
   PubMed Web of Science ®Google Scholar
• HTaniguchi, YKondoh, MEbina, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res 2011;12:93
   PubMedGoogle Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646-64
   PubMed Web of Science ®Google Scholar
• PSpagnolo, CDel Giovane, FLuppi, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010(9):Cd003134
   Google Scholar
• KSharma, JHIx, AVMathew, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011;22(6):1144-51
   PubMed Web of Science ®Google Scholar
• TShimizu, TKuroda, SHata, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998;54(1):99-109
   PubMed Web of Science ®Google Scholar
• QShi, XLiu, YBai, et al. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One 2011;6(11):e28134
   Google Scholar
• TYamazaki, NYamashita, YIzumi, et al. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertens Res 2012;35(1):34-40
   Google Scholar
• ADi Sario, EBendia, GMacarri, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 2004;36(11):744-51
   Google Scholar
• JArmendariz-Borunda, ILyra-Gonzalez, DMedina-Preciado, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg 2012;68(1):22-8
   PubMed Web of Science ®Google Scholar
• TItoh, KKoyabu, AMorimoto, et al. Ameliorative effects of mosapride or Rikkunshi-to on the suppression of gastrointestinal motility by pirfenidone in rats. Jpn Pharmacol Ther 2012;40(5):405-11
   Google Scholar
• YShimizu, YShimoyama, AKawada, et al. Gastrointestinal symptoms in idiopathic pulmonary fibrosis patients treated with pirfenidone and herbal medicine. J Biol Regul Homeost Agents 2014;28(3):433-42
   Google Scholar
• TArai, YInoue, YSasaki, et al. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 2014;52(2):136-43
   PubMedGoogle Scholar
• ELoveman, VRCopley, JLColquitt, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 2014;15:63
   PubMed Web of Science ®Google Scholar
• TIwata, SYoshida, KNagato, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today 2014. [Epup ahead of print]
   Google Scholar
• GRaghu, WCJohnson, DLockhart, YMageto. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999;159(4 Pt 1):1061-9
   PubMed Web of Science ®Google Scholar
• SNagai, KHamada, MShigematsu, et al. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Int Med (Tokyo, Japan) 2002;41(12):1118-23
   PubMed Web of Science ®Google Scholar
• SSakamoto, TItoh, YMuramatsu, et al. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Int Med (Tokyo, Japan) 2013;52(22):2495-501
   Google Scholar
• ROkuda, EHagiwara, TBaba, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 2013;107(9):1431-7
   PubMed Web of Science ®Google Scholar
• TIwasawa, TOgura, FSakai, et al. CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol 2014;83(1):32-8
   Google Scholar
• BLoeh, FDrakopanagiotakis, GPBandelli, et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;191(1):110-13
   PubMed Web of Science ®Google Scholar
• Pirfenidone for treating idiopathic pulmonary fibrosis (NICE technology appraisal guidance). National Institute for Health and Clinical Evidence (NICE); 2013. Available from: http://www.nice.org.uk/guidance/ta282 [Last accessed 1 March 2015]
   Google Scholar
• FDA approves Esbriet to treat idiopathic pulmonary fibrosis. U.S. Food and Drug Administration,2014. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm418991.htm [Last accessed 1 March 2015]
   Google Scholar
• LRicheldi, CJRyerson, JSLee, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67(5):407-11
   PubMed Web of Science ®Google Scholar
• HChiba, MNatsuizaka, HTakahashi. The epidemiology of idiopathic pulmonary fibrosis in Hokkaido. Lung Perspectivces 2012;20(2):243-5
   Google Scholar
• KJeon, MPChung, KSLee, et al. Prognostic factors and causes of death in Korean patients with idiopathic pulmonary fibrosis. Respir Med 2006;100(3):451-7
   Google Scholar
• YMiura, TSaito, YTsunoda, et al. Clinical effect on incidence of acute exacerbation and lung carcinoma of pirfenidone in chronic interstitial pneumonia. Am J Respir Crit Care Med 2014;A6581
   Google Scholar
• CVancheri, MFailla, NCrimi, GRaghu. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010;35(3):496-504
   PubMed Web of Science ®Google Scholar
• SKozono, KOhuchida, DEguchi, et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res 2013;73(7):2345-56
   PubMed Web of Science ®Google Scholar
• IBurghardt, FTritschler, CAOpitz, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun 2007;354(2):542-7
   PubMed Web of Science ®Google Scholar
• YMiura, TSaito, YTsunoda, et al. Clinical effect of pirfenidone on incidence of lung cancer in idiopathic pulmonary fibrosis (P3497). 2014 ERS International Congress; 9 September 2014; Munich
   Google Scholar
• LLMcCormick, YZhang, ETootell, ACGilliam. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol (Baltimore, Md : 1950) 1999;163(10):5693-9
   PubMed Web of Science ®Google Scholar
• YMiura, TSaito, KFujita, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2014;31(3):235-8
   PubMed Web of Science ®Google Scholar
• ZFUdwadia, JBMullerpattan, CBalakrishnan, LRicheldi. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 2015;32(1):50-2
   PubMed Web of Science ®Google Scholar
• AUWells. Interstitial lung disease in systemic sclerosis. Presse Medicale (Paris, France : 1983) 2014;43(10 Pt 2):e329-43
   PubMed Web of Science ®Google Scholar
• CNannini, CPWest, PJErwin, ELMatteson. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008;10(5):R124
   PubMed Web of Science ®Google Scholar
• CMRubino, SMBhavnani, PGAmbrose, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 2009;22(4):279-85
   PubMed Web of Science ®Google Scholar
• YInoue, AAzuma, TOgura, et al. All-case post-marketing surveillance (PMS) of pirfenidone in Japan: clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) [P3369]. 2013 ERS International Congress; Barcelona; 2013
   Google Scholar
• LRicheldi, RMdu Bois, GRaghu, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2071-82
   PubMed Web of Science ®Google Scholar
• TOgura, HTaniguchi, AAzuma, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2014. [Epup ahead of print]
   Google Scholar
• MReck, RKaiser, AMellemgaard, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15(2):143-55
   PubMed Web of Science ®Google Scholar